Special Issue "Selected Papers from the Renin–Angiotensin–Aldosterone System (RAAS)2016: Official Satellite of ISH2016, from September 23 to 24 in Tokyo, Japan"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (13 February 2017).
Interests: hypertension management; blood pressure measurement and variability; cardiac molecular and cellular signalling pathways activated by aldosterone and cortisol; molecular mechanisms and translation research into diabetes; gender differences in ischemic heart disease; blood pressure variability during obstructive sleep apnoea and bereavement
Special Issues and Collections in MDPI journals
Interests: pharmacology and physiology of the renin–angiotensin–aldosterone system; ageing; diabetes; preeclampsia; VEGF inhibition/cancer; endothelin
Interests: Renal Physiology; the renin angiotensin aldosterone; hypertension; clinical nephrology; endocrine hypertension
Interests: hypertension; endocine disease; chronic kidney disease; cardiovascular disease; diabetes melitus; etc.
Interests: lifestyle-related diseases including hypertension; renal disease; diabetes; cardiovascular disease; cancer; etc.
Renin–angiotensin–aldosterone system (RAAS) blockers are the cornerstone of the treatment of cardiovascular disease and nephropathy. While there are currently four types of RAAS blockers (renin inhibitors, ACE inhibitors, AT1 receptor antagonists and mineralocorticoid receptor antagonists), there have been many exciting new developments as well as alternative RAAS targets identified. Recent investigations have revealed a range of unanticipated extrarenal actions of aldosterone, as well as detailed insight in the genetic causes of primary aldosteronism.
This Special Issue will present a selection of contributions from the two-day RAAS2016 Symposium (http://www.congre.co.jp/raas2016/) convened by Presidents Prof. Sadayoshi Ito (Sendai) and Prof. Jan Danser (Rotterdam) in Tokyo 23–24 September, 2016, immediately prior to the 26th Meeting of the International Society of Hypertension (ISH) which will be held in Seoul, Korea.
All speakers presenting a paper at this conference can submit a manuscript for publication. For further information contact the Editorial Office ([email protected]).
Prof Sadayoshi Ito
Prof Jan Danser
Prof Akira Nishiyama
Prof Fumitoshi Satoh
Dr Anastasia S Mihailidou
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Renin–angiotensin–aldosterone system inhibitors
- ACE2-angiotensin-(1-7)-Mas receptor
- Combined AT1 receptor/neprilysin inhibitors (ARNI)
- (Pro)renin receptor
- Primary aldosteronism